Literature DB >> 8396807

Studies on dicistronic polioviruses implicate viral proteinase 2Apro in RNA replication.

A Molla1, A V Paul, M Schmid, S K Jang, E Wimmer.   

Abstract

A dicistronic poliovirus W1-P1/E/P2,3-1 with the genotype [PV]5'NTR-P1-[EMCV]IRES-[PV]P2,3-3'NTR (Molla, Jang, Paul, Reuer, and Wimmer, 1992, Nature 356, 255) was used to investigate whether the viral proteinase 2Apro, whose primary function in proteolytic processing was erased through the insertion of an internal ribosomal entry site (IRES) element into the ORF of the polyprotein, had other function(s) in viral replication. Deletion of 2Apro from W1-P1/E/P2,3-1 rendered the corresponding transcripts unable to replicate whereas partial deletion of 2Apro or an exchange of Cys109 (an amino acid of the catalytic triad of the proteinase) to Ala reduced RNA replication. No cytopathic effects were observed after transfection with any of the three dicistronic constructs containing mutant 2A, and no virus was recovered after attempts to expand a possibly low yield of mutant virus. In contrast, insertion of the IRES of encephalomyocarditis virus (EMCV) into the ORF of the poliovirus polyprotein at the cleavage site between 2Apro and 2B yielded the novel dicistronic virus W1-P1,2A/E/2BC,P3-1 with the genotype [PV]5'NTR-P1-2A-[EMCV]IRES-[PV]2BC-P3-3'NTR, expressing a small plaque phenotype. These results indicate that neither the intact P2 polypeptide nor the cleavage fragment 2AB of P2 is required for viral proliferation. On the other hand, 2Apro appears to be an essential component in RNA replication as no viral RNA synthesis can be observed by reverse transcription/PCR in cells transfected with dicistronic RNA lacking this viral polypeptide.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396807     DOI: 10.1006/viro.1993.1531

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  36 in total

1.  Mapping the genetic determinants of pathogenicity and plaque phenotype in swine vesicular disease virus.

Authors:  T Kanno; D Mackay; T Inoue; G Wilsden; M Yamakawa; R Yamazoe; S Yamaguchi; J Shirai; P Kitching; Y Murakami
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Initiation of poliovirus negative-strand RNA synthesis requires precursor forms of p2 proteins.

Authors:  Christy Jurgens; James B Flanegan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Strand-specific RNA synthesis defects in a poliovirus with a mutation in protein 3A.

Authors:  Natalya L Teterina; Mario S Rinaudo; Ellie Ehrenfeld
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

4.  Viable polioviruses that encode 2A proteins with fluorescent protein tags.

Authors:  Natalya L Teterina; Eric A Levenson; Ellie Ehrenfeld
Journal:  J Virol       Date:  2009-11-25       Impact factor: 5.103

5.  Defective RNA replication by poliovirus mutants deficient in 2A protease cleavage activity.

Authors:  S F Yu; P Benton; M Bovee; J Sessions; R E Lloyd
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

6.  The rhinovirus type 14 genome contains an internally located RNA structure that is required for viral replication.

Authors:  K L McKnight; S M Lemon
Journal:  RNA       Date:  1998-12       Impact factor: 4.942

7.  Protein 2A is not required for Theiler's virus replication.

Authors:  T Michiels; V Dejong; R Rodrigus; C Shaw-Jackson
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

8.  A protein linkage map of the P2 nonstructural proteins of poliovirus.

Authors:  A Cuconati; W Xiang; F Lahser; T Pfister; E Wimmer
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

9.  Genetic map of the calicivirus rabbit hemorrhagic disease virus as deduced from in vitro translation studies.

Authors:  C Wirblich; H J Thiel; G Meyers
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

10.  Poliovirus protein 3AB forms a complex with and stimulates the activity of the viral RNA polymerase, 3Dpol.

Authors:  S J Plotch; O Palant
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.